



Representing Household & Institutional Products

Aerosol - Air Care - Cleaners - Polishes  
Automotive Care - Antimicrobial - Pest Management

April 15, 2013

*Via Courier*

Document Processing Desk  
Office of Pesticide Programs (7508P)  
One Potomac Yard (South Building)  
2777 S. Crystal Drive  
Arlington, VA 22202

**Attention: Mr. José Gayoso, Chemical Review Manager**

**Re: Piperonyl Butoxide Registration Review (GDCI-067501-1063);  
Submitted by Piperonyl Butoxide Task Force II, Company #66045**

Dear Mr. Gayoso:

The Piperonyl Butoxide Task Force II, current members list attached, is pleased to submit three (3) copies of the following reviews of recently submitted aerobic soil and aerobic aquatic metabolism studies:

- "Piperonyl Butoxide: Review of Aerobic Aquatic Metabolism Study," and
- "Piperonyl Butoxide: Review of Aerobic Soil Metabolism Study.

The above submissions address two studies recently submitted by Endura S.p.A and are awaiting MRID number assignment:

- "Aerobic Transformation of Piperonyl Butoxide (PBO) in Water/Sediment Systems (OECD 308).
- "Degradation Rates of Piperonyl Butoxide (PBO) and Selected Metabolites in Soil Under Aerobic Conditions (OECD 307)."

The discussions provided in this submission provide the Agency with a summary of the data submitted by Endura; demonstration that the studies, conducted in compliance with OECD guidelines, are consistent with OPPTS guideline requirements; as well as justification that the foreign soils used in the studies are similar to US soils and as such should be considered acceptable.

This response is the exclusive property of the Piperonyl Butoxide Task Force II. Please provide me with the MRID numbers assigned to each document in this submission.

Please contact me at 202-833-7315 or slittle@cspa.org if you have any questions regarding this submission.

Sincerely,

Susan E. Little  
Executive Director, PIR Program  
for the PB Task Force II

cc: Jose Gayoso, transmittal letter only, via email

**Members of the Piperonyl Butoxide Task Force II  
April 2013**

Endura SpA

McLaughlin Gormley King Company

Prentiss, Incorporated

S.C. Johnson & Son, Inc.

Valent BioSciences Corporation